1921
Volume 96, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Cutaneous leishmaniasis (CL) by is associated with decreasing cure rates in Brazil. Standard treatment with pentavalent antimony (Sb) cures only 50–60% of the cases. The immunopathogenesis of CL ulcer is associated with high interferon-γ and tumor necrosis factor (TNF) production. Pentoxifylline, a TNF inhibitor, has been successfully used in association with Sb in mucosal and cutaneous leishmaniasis. This randomized, double-blind, and placebo-controlled trial aimed to evaluate the efficacy and safety of oral pentoxifylline plus Sb versus placebo plus Sb in patients with CL in Bahia, Brazil. A total of 164 patients were randomized in two groups to receive the combination or the monotherapy. Cure rate 6 months after treatment was 45% in the pentoxifylline group and 43% in the control group. There was also no difference between the groups regarding the healing time (99.7 ± 66.2 days and 98.1 ± 72.7 days, respectively). Adverse events were more common in the pentoxifylline group (37.8%), versus 23% in the placebo group. This trial shows that Sb combined therapy with pentoxifylline is not more effective than Sb monotherapy in the treatment of CL caused by .

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-0435
2017-02-27
2020-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/5/1155.html?itemId=/content/journals/10.4269/ajtmh.16-0435&mimeType=html&fmt=ahah

References

  1. Grimaldi G Jr, Tesh RB, McMahon-Pratt D, 1989. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 41: 687725.
    [Google Scholar]
  2. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.[Crossref]
    [Google Scholar]
  3. Machado P, Araújo C, Da Silva AT, Almeida RP, D'Oliveira A Jr, Bittencourt A, Carvalho EM, 2002. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 34: E69E73.[Crossref]
    [Google Scholar]
  4. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ, 2005. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett 101: 226230.[Crossref]
    [Google Scholar]
  5. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM, 1998. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 31: 143148.[Crossref]
    [Google Scholar]
  6. Faria DR, Souza PE, Durães FV, Carvalho EM, Gollob KJ, Machado PR, Dutra WO, 2009. Recruitment of CD8+ T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol 31: 432439.[Crossref]
    [Google Scholar]
  7. Lessa H, Machado P, Lima F, Cruz A, Bacellar O, Guerreiro J, Carvalho EM, 2001. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65: 8789.
    [Google Scholar]
  8. Machado PRL, Lessa H, Lessa M, Guimarães LH, Bang H, Ho J, Carvalho EM, 2007. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44: 788793.[Crossref]
    [Google Scholar]
  9. Sadeghian G, Nilforoushzadeh MA, 2006. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 45: 819821.[Crossref]
    [Google Scholar]
  10. Brito G, Dourado M, Polari L, Celestino D, Carvalho LP, Queiroz A, Carvalho EM, Machado PRL, Passos S, 2014. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 90: 617620.[Crossref]
    [Google Scholar]
  11. Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, Miranda-Verástegui C, Lazo M, Loayza-Muro R, De Doncker S, Maurer A, Chappuis F, Dujardin JC, Llanos-Cuentas A, 2007. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 195: 18461851.[Crossref]
    [Google Scholar]
  12. Bafica A, Oliveira F, Freitas L, Nascimento EG, Barral A, 2003. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol 42: 203207.[Crossref]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0435
Loading
/content/journals/10.4269/ajtmh.16-0435
Loading

Data & Media loading...

  • Received : 01 Jun 2016
  • Accepted : 31 Dec 2016
  • Published online : 27 Feb 2017
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error